ID   S_M6R1
AC   CVCL_HG09
DR   CancerTools; 152839
DR   Wikidata; Q54951555
DR   Ximbio; 152839
RX   PubMed=27323823;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:134602; MI-63.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61His (c.183A>T); ClinVar=VCV000045117; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Derived from sampling site: Bone; femur.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_1697 ! SJSA-1
SX   Male
AG   19Y
CA   Cancer cell line
DT   Created: 01-12-16; Last updated: 23-06-22; Version: 12
//
RX   PubMed=27323823; DOI=10.18632/oncotarget.10073;
RA   Drummond C.J., Esfandiari A., Liu J.-F., Lu X.-H., Hutton C.,
RA   Jackson J., Bennaceur K., Xu Q., Makimanejavali A.R., Del Bello F.,
RA   Piergentili A., Newell D.R., Hardcastle I.R., Griffin R.J., Lunec J.;
RT   "TP53 mutant MDM2-amplified cell lines selected for resistance to
RT   MDM2-p53 binding antagonists retain sensitivity to ionizing
RT   radiation.";
RL   Oncotarget 7:46203-46218(2016).
//